L. Mayo discusses the study by Brown et al, in this issue of EMBO Mol Med, that uses genetically engineered mouse models to determine the functional consequences of missense and loss of function mutations in Fbxw7, Pten, and Tp53 in the context of high‐risk endometrial cancers. This evidence concerns the gene PTEN and endometrial cancer.